Actively Recruiting
Autoimmunity After Checkpoint Blockade
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-01-08
600
Participants Needed
1
Research Sites
331 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
CONDITIONS
Official Title
Autoimmunity After Checkpoint Blockade
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A diagnosis of cancer and prescription for a checkpoint inhibitor
You will not qualify if you...
- Any subjects not willing or able to give consent
- Children under the age of 18
- A history of transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
K
Kyra J Sacksith
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here